SPAC Seeks Shareholder Approval to Extend Merger Deadline, Avoid Liquidation
PGAC is trading near its 52-week low of $9.89 (6.7% above the low) on light trading volume (0.2× avg).
Summary
Pantages Capital Acquisition Corp. has filed a definitive proxy statement for a June 3, 2026, shareholder meeting to vote on extending its business combination deadline to June 6, 2027, a critical step to avoid liquidation following a recent 'going concern' warning.
Key Events · Corporate Governance and Compliance · PGAC
-
Shareholder Meeting Scheduled
An Extraordinary General Meeting will be held on June 3, 2026, to vote on critical proposals.
-
Extension Proposal to Avoid Liquidation
Shareholders will vote on amending the company's charter to extend the business combination deadline from June 6, 2026, to June 6, 2027, on a month-to-month basis. Failure to approve this would lead to liquidation.
-
Trust Agreement Amendment Proposed
A vote is required to amend the Investment Trust Agreement, allowing monthly extensions by depositing $0.033 per non-redeemed Class A ordinary share (up to $60,000 per month) into the trust account.
-
Redemption Rights for Public Shareholders
Public shareholders can redeem their shares for approximately $10.57 per share (based on the May 20, 2026, trust account balance), slightly above the current market price of $10.55.
Analysis · PGAC · Real Estate & Construction
This definitive proxy statement is critical as it outlines the proposals for a shareholder vote on June 3, 2026, that will determine the immediate future of the SPAC. Following a recent 'going concern' warning, the company is seeking to extend its business combination deadline to June 6, 2027. Failure to approve these extensions would force the company to liquidate by June 6, 2026, making this vote crucial for its survival and the completion of its proposed merger with MacMines Austasia.
At the time of this filing, PGAC was trading at $10.55 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $93.6M. The 52-week trading range was $9.89 to $10.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.